CO2018013692A2 - Composiciones para el tratamiento o prevención de síntomas vasomotores - Google Patents

Composiciones para el tratamiento o prevención de síntomas vasomotores

Info

Publication number
CO2018013692A2
CO2018013692A2 CONC2018/0013692A CO2018013692A CO2018013692A2 CO 2018013692 A2 CO2018013692 A2 CO 2018013692A2 CO 2018013692 A CO2018013692 A CO 2018013692A CO 2018013692 A2 CO2018013692 A2 CO 2018013692A2
Authority
CO
Colombia
Prior art keywords
compositions
vasomotor symptoms
prevention
treatment
trpm8
Prior art date
Application number
CONC2018/0013692A
Other languages
English (en)
Inventor
Joseph M Palumbo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CO2018013692A2 publication Critical patent/CO2018013692A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se dirige a composiciones y métodos para tratar o prevenir síntomas vasomotores tal como bochornos, que comprende un antagonista del receptor de potencial transitorio de melastatina 8 (TRPM8) y administrar un antagonista del TRPM8, respectivamente.
CONC2018/0013692A 2016-06-13 2018-12-18 Composiciones para el tratamiento o prevención de síntomas vasomotores CO2018013692A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349179P 2016-06-13 2016-06-13
PCT/JP2017/021569 WO2017217351A1 (en) 2016-06-13 2017-06-12 Compositions for treating or preventing vasomotor symptoms

Publications (1)

Publication Number Publication Date
CO2018013692A2 true CO2018013692A2 (es) 2019-01-18

Family

ID=59101629

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013692A CO2018013692A2 (es) 2016-06-13 2018-12-18 Composiciones para el tratamiento o prevención de síntomas vasomotores

Country Status (17)

Country Link
US (2) US10993939B2 (es)
EP (2) EP3468557B1 (es)
JP (1) JP6943887B2 (es)
KR (2) KR20190017800A (es)
CN (4) CN113384577A (es)
AU (2) AU2017285609B2 (es)
BR (1) BR112018075403A2 (es)
CA (1) CA3022808A1 (es)
CO (1) CO2018013692A2 (es)
ES (1) ES2957232T3 (es)
IL (1) IL262664B (es)
MX (1) MX2018015399A (es)
PH (1) PH12018502618A1 (es)
RU (1) RU2768875C2 (es)
SG (1) SG11201809802PA (es)
TW (1) TWI739850B (es)
WO (1) WO2017217351A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085292A1 (en) * 2017-12-19 2019-06-27 Mitsubishi Tanabe Pharma Corporation Compositions and methods for treating or preventing vasomotor symptoms
CA3128500A1 (en) * 2019-02-01 2020-08-06 Marshall University Research Corporation Transient receptor potential melastatin 8 (trpm8) antagonists and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006244074B2 (en) * 2005-05-09 2012-12-13 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
WO2009073788A1 (en) * 2007-12-07 2009-06-11 Firestone Leigh H Compositions and methods for treating menopausal females
US8436041B2 (en) 2008-12-18 2013-05-07 Janssen Pharmaceutica, Nv Sulfamides as TRPM8 modulators
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
RU2011148937A (ru) 2009-05-01 2013-06-10 Раквалиа Фарма Инк. Производные сульфамоилбензойной кислоты в качестве антагонистов trpm8
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
JP5684401B2 (ja) 2011-03-16 2015-03-11 田辺三菱製薬株式会社 Ｔｒｐｍ８遮断効果を有するスルホンアミド化合物
CA2839699A1 (en) * 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
SI2793883T1 (en) 2011-12-19 2018-08-31 Dompe Farmaceutici S.P.A. Antagonists TRPM8
WO2014042238A1 (ja) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 スルホンアミド化合物
JP5985453B2 (ja) * 2012-09-14 2016-09-06 田辺三菱製薬株式会社 医薬組成物
ES2856892T3 (es) * 2013-10-22 2021-09-28 Iview Therapeutics Inc Compuestos de di-isopropil-fosfinoil-alcano (DAPA) como agentes topicos para el tratamiento de molestias sensoriales

Also Published As

Publication number Publication date
EP4140484A1 (en) 2023-03-01
JP6943887B2 (ja) 2021-10-06
SG11201809802PA (en) 2018-12-28
BR112018075403A2 (pt) 2019-03-19
IL262664A (en) 2018-12-31
CN109310689A (zh) 2019-02-05
CN113384577A (zh) 2021-09-14
EP3468557A1 (en) 2019-04-17
JP2019517573A (ja) 2019-06-24
KR20230005413A (ko) 2023-01-09
CA3022808A1 (en) 2017-12-21
TWI739850B (zh) 2021-09-21
ES2957232T3 (es) 2024-01-15
KR20190017800A (ko) 2019-02-20
AU2017285609B2 (en) 2022-08-18
TW201803595A (zh) 2018-02-01
EP3468557B1 (en) 2023-07-26
US10993939B2 (en) 2021-05-04
RU2019100424A (ru) 2020-07-15
WO2017217351A1 (en) 2017-12-21
MX2018015399A (es) 2019-04-29
RU2768875C2 (ru) 2022-03-25
CN113398124A (zh) 2021-09-17
PH12018502618A1 (en) 2019-10-07
AU2017285609A1 (en) 2019-01-03
CN114748624A (zh) 2022-07-15
IL262664B (en) 2021-10-31
AU2022211877A1 (en) 2022-09-01
US20210177830A1 (en) 2021-06-17
RU2019100424A3 (es) 2020-09-24
US20190142821A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
ECSP17028463A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
CO2018013692A2 (es) Composiciones para el tratamiento o prevención de síntomas vasomotores
BR112016016098A2 (pt) Compostos orgânicos
NI201500172A (es) Composiciones farmacéuticas
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
BR112017017064A8 (pt) “composição farmacêutica para prevenir ou tratar câncer, e uso do composto de fórmula i”